Rekvina Laboratories Ltd (VINRKLB) — shareholding pattern, promoter holding, financials and share price
About Rekvina Laboratories Ltd (VINRKLB)
Rekvina Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VINRKLB and on the BSE under scrip code 526075. Its ISIN is INE092O01028.
[1] Rekvina Laboratories Limited is engaged in the manufacturing and marketing of pharmaceutical formulations. [2]
Listed peers in Pharmaceuticals: Mono Pharmacare Ltd, Centuple Global Ltd, Desh Rakshak Aushdhalaya Ltd, Zenith Health Care Ltd, Saroja Pharma Industries India Ltd, Starsource Multitrade Ltd.
Valuation & Returns
28 Jul 2026At ₹25.3 a share on 28 Jul 2026, Rekvina Laboratories Ltd (VINRKLB) was valued at a price-to-earnings ratio of -61x against an industry P/E of 37.21x. Solomo computes return on equity of 20.74% and return on capital employed of -104.17% from filed results.
- P/E
- -61x
- Industry P/E
- 37.21x
- EPS (TTM)
- ₹-0.23
- Book value / share
- ₹-2.03
- ROE
- 20.74%
- ROCE
- -104.17%
- ROA
- -21.01%
- Debt / equity
- -1.2x
- Dividend yield
- 0%
- EBITDA margin
- -19.69%
- 52-week range
- ₹6.75 – ₹46.65
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Rekvina Laboratories Ltd (VINRKLB) reported revenue of ₹1.27 crore, net profit of ₹-0.25 crore and earnings per share of ₹-0.21. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹0.72 crore and net profit ₹-0.06 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | -0.04 | 0 | 0 | 0 | 1.27 |
| Net profit (₹ cr) | -0.08 | 0 | -0.02 | -0.14 | -0.25 |
| EPS (₹) | -0.07 | 0 | -0.02 | -0.12 | -0.21 |
| Measure | 1Y |
|---|---|
| Profit growth | -600.00% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 41.3% of Rekvina Laboratories Ltd (VINRKLB) (unchanged from the previous quarter). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: NIRAVBHAI JASHUBHAI PATEL 6.47%, DILSAN PHARMA IMPEX PRIVATE LIMITED 6.4%, HUF 6.04%, ABHIJIT DHARMESHBHAI MEHTA 4.46%, ARUNKUMAR NARSINGH RAO 3.93%, KISHORBHAI J SURATWALA 3.81%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 41.3% | - | - | - | 58.7% |
| Mar 2026 | 41.3% | - | - | - | 58.7% |
| Dec 2025 | 41.3% | - | - | - | 58.7% |
| Sep 2025 | 41.3% | - | - | - | 58.7% |
| Jun 2025 | 41.3% | - | - | - | 58.7% |
| Mar 2025 | 41.3% | - | - | - | 58.7% |
| Dec 2024 | 41.3% | - | - | - | 58.7% |
| Sep 2024 | 41.3% | - | - | - | 58.7% |